Panic Disorder: psilocybin research evidence
Dedicated controlled trials of psilocybin for primary panic disorder are largely absent. Current material is limited to comorbid observations, public-health toxicology noting acute panic provocation risk, and theoretical mechanistic discussion.
Last reviewed: 2026-07-26
Evidence narrative
Why this page exists
Panic disorder is clinically important and frequently requested in psychedelic discussions, but it should not be collapsed into general anxiety evidence. PSILORIS tracks it separately because primary panic pathophysiology and trial evidence differ from GAD and cancer-related anxiety.
What the evidence currently is (and is not)
- There is no dedicated modern Phase 2/3 psilocybin RCT for primary panic disorder in the current curated set.
- Panic appears mainly as a comorbid diagnosis in broader cohorts (for example demoralization studies) or as an acute adverse event risk in unsupervised settings.
- Public-health toxicology (van Amsterdam et al., 2011) judged overall magic-mushroom dependence potential low, while explicitly flagging unpredictable acute panic attacks as a concern.
Why status is candidate, not promising
Candidate status reflects biological and clinical plausibility plus research interest, not confirmed efficacy. Until condition-specific controlled trials exist, therapeutic claims for primary panic disorder remain premature.
Safety emphasis
Psilocybin can acutely raise heart rate, blood pressure, and somatic salience. In panic disorder, those sensations may resemble panic onset. Structured preparation, medical screening, and professional supervision are especially important; unsupervised use is not endorsed by PSILORIS.
Citations
[1] systematic review · 2024
Adverse psychiatric effects of psychedelic drugs: a systematic review of case reports
Yildirim B, Sahin SS, Gee A, et al. — Psychological Medicine
Compiled credible case reports of schizophrenia-spectrum and major affective disorders after psychedelic use; recovery was common for affective presentations but less consistent for schizophrenia-spectrum outcomes.
DOI: 10.1017/S0033291724002496
[2] open label · 2020
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men
Anderson BT, Danforth A, Daroff R, et al. — EClinicalMedicine
Group psilocybin-assisted therapy showed feasibility and reductions in demoralization, illustrating candidate use beyond classical mood-disorder indications.
DOI: 10.1016/j.eclinm.2020.100539
[3] review · 2011
Harm potential of magic mushroom use: a review
van Amsterdam J, Opperhuizen A, van den Brink W — Regulatory Toxicology and Pharmacology
Dutch CAM risk assessment concluded low dependence potential overall, while highlighting unpredictable acute panic-attack provocation as a key unsupervised-use concern.
DOI: 10.1016/j.yrtph.2011.01.006
[4] review · 2008
Human hallucinogen research: guidelines for safety
Johnson MW, Richards WA, Griffiths RR — Journal of Psychopharmacology
Foundational safety framework for human psychedelic research covering screening, set and setting, session monitoring, and aftercare.
DOI: 10.1177/0269881108093587